- Home
- VTVT vs TELO Comparison
VTVT vs TELO Comparison
Compare VTVT & TELO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTVT
- TELO
- Stock Information
- Founded
- VTVT 2015
- TELO 2021
- Country
- VTVT United States
- TELO United States
- Employees
- VTVT N/A
- TELO N/A
- Industry
- VTVT Biotechnology: Pharmaceutical Preparations
- TELO
- Sector
- VTVT Health Care
- TELO
- Exchange
- VTVT Nasdaq
- TELO NYSE
- Market Cap
- VTVT 45.8M
- TELO 52.4M
- IPO Year
- VTVT 2015
- TELO 2024
- Fundamental
- Price
- VTVT $14.95
- TELO $1.96
- Analyst Decision
- VTVT Strong Buy
- TELO
- Analyst Count
- VTVT 2
- TELO 0
- Target Price
- VTVT $35.50
- TELO N/A
- AVG Volume (30 Days)
- VTVT 3.2K
- TELO 9.1M
- Earning Date
- VTVT 08-07-2025
- TELO 08-12-2025
- Dividend Yield
- VTVT N/A
- TELO N/A
- EPS Growth
- VTVT N/A
- TELO N/A
- EPS
- VTVT N/A
- TELO N/A
- Revenue
- VTVT $17,000.00
- TELO N/A
- Revenue This Year
- VTVT N/A
- TELO N/A
- Revenue Next Year
- VTVT N/A
- TELO N/A
- P/E Ratio
- VTVT N/A
- TELO N/A
- Revenue Growth
- VTVT N/A
- TELO N/A
- 52 Week Low
- VTVT $12.58
- TELO $1.12
- 52 Week High
- VTVT $26.99
- TELO $8.40
- Technical
- Relative Strength Index (RSI)
- VTVT 38.23
- TELO 55.51
- Support Level
- VTVT $15.52
- TELO $2.00
- Resistance Level
- VTVT $17.46
- TELO $2.44
- Average True Range (ATR)
- VTVT 0.47
- TELO 0.22
- MACD
- VTVT -0.15
- TELO 0.08
- Stochastic Oscillator
- VTVT 6.05
- TELO 42.42
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
About TELO TELOMIR PHARMACEUTICALS INC
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.